590 related articles for article (PubMed ID: 17392714)
1. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
Taplin ME; Balk SP
J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of prostate cancer progression to androgen independence.
McPhaul MJ
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of resistance to antiandrogen therapy.
Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
[TBL] [Abstract][Full Text] [Related]
6. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
Wang G; Sadar MD
J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
8. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
9. Alterations of androgen receptor in prostate cancer.
Linja MJ; Visakorpi T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
[TBL] [Abstract][Full Text] [Related]
10. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
11. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
12. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
13. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
14. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
[TBL] [Abstract][Full Text] [Related]
15. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
17. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
Kaarbø M; Klokk TI; Saatcioglu F
Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial androgen receptor targeted therapy for prostate cancer.
Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
[TBL] [Abstract][Full Text] [Related]
19. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.
Zegarra-Moro OL; Schmidt LJ; Huang H; Tindall DJ
Cancer Res; 2002 Feb; 62(4):1008-13. PubMed ID: 11861374
[TBL] [Abstract][Full Text] [Related]
20. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
